Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is

Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. The company – which tests infectious

hVIVO plc, a specialist in testing infectious and respiratory disease products using human challenge clinical trials, has reported a 16% increase in revenue for 2023 to £56m. The company, listed

Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation

Introduction A biotech company developing a treatment for cancer and immune disorders planned to conduct their Phase 1b clinical trial in the United States (US). They approached Venn Life Sciences

Andrew will be discussing new advances in respiratory virus challenge models improving their value for vaccine efficacy testing and host response disease monitoring. The World Vaccine Congress is an award-winning

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and

Clinical trials are essential processes in the field of medicine, helping to determine the safety and effectiveness of new treatments, drugs, or medical procedures. These trials involve volunteers who agree to participate